Boche D, Gordon MN (2021) Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. Alzheimer’s & Dementia doi: 10.1002/alz.12389, PMID: 34223696.
PI: Torsten Falk, PhD, Univ of AZ; Co-Inv: Kathy Steece-Collier were awarded $262,028 from NINDS for “Mechanisms of low-dose ketamine treatment for Parkinson's disease”. 07/01/2021 – 06/30/2025.
Sortwell CE, Hacker ML, Fischer DL, Konrad PE, Davis TL, Neimat JS, Wang L, Song Y, Mattingly ZR,Cole-Strauss A, Lipton JW and Charles PD (2021)BDNF rs6265 genotype influences outcomes of pharmacotherapy and subthalamic nucleus deep brain stimulation in early-stage Parkinson’s disease. Neuromodulation, Jul 20. doi: 10.1111/ner.13504. PMID: 34288271
Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-beta Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimer's Disease: A Targeted Transcriptome Analysis. Ma C, Hunt JB, Kovalenko A, Liang H, Selenica MB, Orr MB, Zhang B, Gensel JC, Feola DJ, Gordon MN,Morgan D, Bickford PC, Lee DC.Front Immunol. 2021 May 11;12:628156. doi: 10.3389/fimmu.2021.628156. eCollection 2021.PMID: 34046031
R. Luedtke (University of North Texas, PI) and D. Morgan (MSU, PI) were awarded $680,000 from NIH/NIA for “Discovery of Functionally selective Alzheimer’s disease therapeutics”. MSU receives $180,000 for this year with possible additional funds for NCE. June 2021 – May 2022.
Dave Morgan has patented Inhibition of Amyloid- Protein Fibrils Using Cactus Mucilage Extracts. Patent No. 10,946,056 on March 16, 2021